Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

HHS had argued that Vertex's plan to cover fertility services for some patients that took its gene therapy would violate anti-kickback and inducement laws.